ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%
ST SC Pharmaceuticals released its semi-annual report for 2025, with operating revenue of 84.1221 million yuan, a year-on-year decrease of 11.35%. The net loss attributable to shareholders of the listed company was 18.4666 million yuan, a year-on-year increase of 8.97%. The net loss after deducting non-recurring gains and losses was 21.0158 million yuan, a year-on-year increase of 18.34%. The basic loss per share was 0.0445 yuan
According to the Zhitong Finance APP, *ST Pharmaceuticals (002693.SZ) released its semi-annual report for 2025, showing an operating income of 84.1221 million yuan, a year-on-year decrease of 11.35%. The net loss attributable to shareholders of the listed company was 18.4666 million yuan, a year-on-year increase of 8.97%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 21.0158 million yuan, a year-on-year increase of 18.34%. The basic loss per share was 0.0445 yuan
